{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:29:30Z","timestamp":1791142170050,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T00:00:00Z","timestamp":1319155200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00213-011-2534-7","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T05:40:49Z","timestamp":1319089249000},"page":"195-203","source":"Crossref","is-referenced-by-count":8,"title":["Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat"],"prefix":"10.1007","volume":"221","author":[{"given":"Maria","family":"Meringolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Brusadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Antonilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nencini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Badiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,21]]},"reference":[{"key":"2534_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpain.2003.09.003","volume":"8","author":"G Andersen","year":"2004","unstructured":"Andersen G, Sjogren P, Hansen SH, Jensen NH, Christrup L (2004) Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. Eur J Pain 8:263\u2013271","journal-title":"Eur J Pain"},{"key":"2534_CR2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00213-003-1531-x","volume":"170","author":"L Antonilli","year":"2003","unstructured":"Antonilli L, Semeraro F, Suriano C, Signore L, Nencini P (2003a) High levels of morphine-6-glucuronide in street heroin addicts. Psychopharmacology (Berl) 170:200\u2013204","journal-title":"Psychopharmacology (Berl)"},{"key":"2534_CR3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1124\/jpet.103.055467","volume":"307","author":"L Antonilli","year":"2003","unstructured":"Antonilli L, Suriano C, Paolone G, Badiani A, Nencini P (2003b) Repeated exposures to heroin and\/or cadmium alter the rate of formation of morphine glucuronides in the rat. J Pharmacol Exp Ther 307:651\u2013660","journal-title":"J Pharmacol Exp Ther"},{"key":"2534_CR4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00213-005-0030-7","volume":"182","author":"L Antonilli","year":"2005","unstructured":"Antonilli L, Petecchia E, Caprioli D, Badiani A, Nencini P (2005) Effect of repeated administrations of heroin, naltrexone, methadone and alcohol on morphine glucuronidation in the rat. Psychopharmacology 182:52\u201364","journal-title":"Psychopharmacology"},{"key":"2534_CR5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejpain.2010.09.007","volume":"15","author":"AR Binning","year":"2011","unstructured":"Binning AR, Przesmycki K, Sowinski P, Morrison LM, Smith TW, Marcus P, Lees JP, Dahan A (2011) A randomised controlled trial on the efficacy and side-effect profile (nausea\/vomiting\/sedation) of morphine-6-glucuronide versus morphine for post-operative pain relief after major abdominal surgery. Eur J Pain 15:402\u2013408","journal-title":"Eur J Pain"},{"key":"2534_CR6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0022-3565(24)36961-7","volume":"282","author":"GP Brown","year":"1997","unstructured":"Brown GP, Yang K, Ouerfelli O, Standifer KM, Byrd D, Pasternak GW (1997) 3H-Morphine-6beta-glucuronide binding in brain membranes and an MOR-1-transfected cell line. J Pharmacol Exp Ther 282:1291\u20131297","journal-title":"J Pharmacol Exp Ther"},{"key":"2534_CR7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-6576.1997.tb04625.x","volume":"41","author":"LL Christrup","year":"1997","unstructured":"Christrup LL (1997) Morphine metabolites. Acta Anaesthesiol Scand 41:116\u2013122","journal-title":"Acta Anaesthesiol Scand"},{"key":"2534_CR8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3959(97)00142-5","volume":"74","author":"CC Faura","year":"1998","unstructured":"Faura CC, Collins SL, Moore RA, McQuay HJ (1998) Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 74:43\u201353","journal-title":"Pain"},{"key":"2534_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-3565(25)10743-X","volume":"262","author":"B Frances","year":"1992","unstructured":"Frances B, Gout R, Monsarrat B, Cros J, Zajac JM (1992) Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 262:25\u201331","journal-title":"J Pharmacol Exp Ther"},{"key":"2534_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(25)26118-3","volume":"133","author":"HF Fraser","year":"1961","unstructured":"Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) \u201cAttitude\u201d of opiate addicts toward opiate-like drugs. (B) A short-term \u201cdirect\u201d addiction test. J Pharmacol Exp Ther 133:371\u2013387","journal-title":"J Pharmacol Exp Ther"},{"key":"2534_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(91)90199-Z","volume":"193","author":"QL Gong","year":"1991","unstructured":"Gong QL, Hedner T, Hedner J, Bjorkman R, Nordberg G (1991) Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6- glucuronide and morphine-3-glucuronide. Eur J Pharmacol 193:47\u201356","journal-title":"Eur J Pharmacol"},{"key":"2534_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.drugalcdep.2008.05.008","volume":"98","author":"M Graziani","year":"2008","unstructured":"Graziani M, Antonilli L, Togna AR, Brusadin V, Viola S, Togna G, Badiani A, Nencini P (2008) Non-opioid induction of morphine-6-glucuronide us is elicited by prolonged exposure of rat hepatocytes to heroin. Drug Alcohol Depend 98:179\u2013184","journal-title":"Drug Alcohol Depend"},{"key":"2534_CR13","first-page":"547","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"HB Gutstein","year":"2006","unstructured":"Gutstein HB, Akil H (2006) Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 547\u2013590","edition":"11"},{"key":"2534_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0169-328X(97)00353-7","volume":"54","author":"HH Loh","year":"1998","unstructured":"Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN (1998) \u03bc Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol Brain Res 54:321\u2013326","journal-title":"Mol Brain Res"},{"issue":"5 Suppl","key":"2534_CR15","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.jpainsymman.2005.01.012","volume":"29","author":"J Lotsch","year":"2005","unstructured":"Lotsch J (2005) Pharmacokinetic\u2013pharmacodynamic modeling of opioids. J Pain Symptom Manage 29(5 Suppl):S90\u2013S103","journal-title":"J Pain Symptom Manage"},{"key":"2534_CR16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00000542-200210000-00011","volume":"97","author":"J Lotsch","year":"2002","unstructured":"Lotsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G (2002) Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97:814\u2013819","journal-title":"Anesthesiology"},{"key":"2534_CR17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00018-002-8449-z","volume":"59","author":"K Mantione","year":"2002","unstructured":"Mantione K, Zhu W, Rialas C, Casares F, Cadet P, Franklin AL, Tonnesen J, Stefano GB (2002) Morphine-6-glucuronide stimulates nitric oxide release in mussel neural tissues: evidence for a morphine-6-glucuronide opiate receptor subtype. Cell Mol Life Sci 59:570\u2013574","journal-title":"Cell Mol Life Sci"},{"key":"2534_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02244907","volume":"112","author":"A Markou","year":"1993","unstructured":"Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF (1993) Animal models of drug craving. Psychopharmacology (Berl) 112:163\u2013182","journal-title":"Psychopharmacology (Berl)"},{"key":"2534_CR19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3565(25)26119-5","volume":"133","author":"WR Martin","year":"1961","unstructured":"Martin WR, Fraser HF (1961) A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J Pharmacol Exp Ther 133:388\u2013399","journal-title":"J Pharmacol Exp Ther"},{"key":"2534_CR20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/383819a0","volume":"383","author":"HWD Matthes","year":"1996","unstructured":"Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Doll\u00e9 P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the \u03bc-opioid-receptor gene. Nature 383:819\u2013823","journal-title":"Nature"},{"key":"2534_CR21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1365-2125.2002.t01-1-01689.x","volume":"54","author":"I Meineke","year":"2002","unstructured":"Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, Prange HW, Gleiter CH, Brockmoller J (2002) Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 54:592\u2013603","journal-title":"Br J Clin Pharmacol"},{"key":"2534_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/03602539608994011","volume":"28","author":"RW Milne","year":"1996","unstructured":"Milne RW, Nation RL, Somogyi AA (1996) The disposition of morphine and its 3 and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28:345\u2013472","journal-title":"Drug Metab Rev"},{"key":"2534_CR23","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/sj.bjp.0703697","volume":"131","author":"PB Osborne","year":"2000","unstructured":"Osborne PB, Chieng B, Christie MJ (2000) Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus. Br J Pharmacol 131:1422\u20131428","journal-title":"Br J Pharmacol"},{"key":"2534_CR24","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1073\/pnas.0811586106","volume":"106","author":"YX Pan","year":"2009","unstructured":"Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW (2009) Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A 106:4917\u20134922","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2534_CR25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3565(25)20832-1","volume":"251","author":"D Paul","year":"1989","unstructured":"Paul D, Standifer KM, Inturrisi CE, Pasternak GW (1989) Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251:477\u2013483","journal-title":"J Pharmacol Exp Ther"},{"key":"2534_CR26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/ndt\/14.4.903","volume":"14","author":"C Pauli-Magnus","year":"1999","unstructured":"Pauli-Magnus C, Hofmann U, Mikus G, Kuhlmann U, Mettang T (1999) Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 14:903\u2013909","journal-title":"Nephrol Dial Transplant"},{"key":"2534_CR27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mcp.2000.111934","volume":"68","author":"RT Penson","year":"2000","unstructured":"Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML (2000) Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 68:667\u2013676","journal-title":"Clin Pharmacol Ther"},{"key":"2534_CR28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00265969","volume":"38","author":"GM Peterson","year":"1990","unstructured":"Peterson GM, Randall CT, Paterson J (1990) Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 38:121\u2013124","journal-title":"Eur J Clin Pharmacol"},{"key":"2534_CR29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00000542-200401000-00021","volume":"100","author":"R Romberg","year":"2004","unstructured":"Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A (2004) Pharmacokinetic\u2013pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100:120\u2013133","journal-title":"Anesthesiology"},{"key":"2534_CR30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0014-5793(95)00757-Z","volume":"369","author":"GC Rossi","year":"1995","unstructured":"Rossi GC, Pan Y-X, Brown GP, Pasternak GW (1995a) Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6\u03b2-glucuronide receptor. FEBS Lett 369:192\u2013196","journal-title":"FEBS Lett"},{"key":"2534_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0304-3940(95)11977-5","volume":"198","author":"GC Rossi","year":"1995","unstructured":"Rossi GC, Standifer KM, Pasternak GW (1995b) Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neurosci Lett 198:99\u2013102","journal-title":"Neurosci Lett"},{"key":"2534_CR32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11481-008-9137-z","volume":"4","author":"BE Sawaya","year":"2009","unstructured":"Sawaya BE, Deshmane SL, Mukerjee R, Fan S, Khalili K (2009) TNF alpha production in morphine-treated human neural cells is NF-kappaB-dependent. J Neuroimmune Pharmacol 4:140\u2013149","journal-title":"J Neuroimmune Pharmacol"},{"key":"2534_CR33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/5706","volume":"2","author":"AGP Schuller","year":"1999","unstructured":"Schuller AGP, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME (1999) Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151\u2013156","journal-title":"Nat Neurosci"},{"key":"2534_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1067\/mcp.2003.5","volume":"73","author":"C Skarke","year":"2003","unstructured":"Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J (2003) Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73:107\u2013121","journal-title":"Clin Pharmacol Ther"},{"key":"2534_CR35","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1073\/pnas.94.4.1544","volume":"94","author":"I Sora","year":"1997","unstructured":"Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544\u20131549","journal-title":"Proc Natl Acad Sci USA"},{"key":"2534_CR36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bjp.0702873","volume":"128","author":"F Stain-Texier","year":"1999","unstructured":"Stain-Texier F, Boschi G, Sandouk P, Schermann JM (1999) Elevated concentrations of morphine 6-beta-d-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol 128:917\u2013924","journal-title":"Br J Pharmacol"},{"key":"2534_CR37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejps.2004.09.009","volume":"24","author":"K Tunblad","year":"2005","unstructured":"Tunblad K, Hammarlund-Udenaes M, Jonsson EN (2005) Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. Eur J Pharm Sci 24:49\u201357","journal-title":"Eur J Pharm Sci"},{"key":"2534_CR38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0006-2952(01)00761-4","volume":"62","author":"C Ulens","year":"2001","unstructured":"Ulens C, Baker L, Ratka A, Waumans D, Tytgat J (2001) Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 62:1273\u20131282","journal-title":"Biochem Pharmacol"},{"key":"2534_CR39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/5706","volume":"2","author":"EM Unterwald","year":"1999","unstructured":"Unterwald EM, Pasternak GW, Pintar JE (1999) Retention of heroin and morphine-6\u03b2-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151\u2013156","journal-title":"Nat Neurosci"},{"key":"2534_CR40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1161\/01.RES.0000065169.23780.0E","volume":"92","author":"C Ventura","year":"2003","unstructured":"Ventura C, Zinellu E, Maninchedda E, Maioli M (2003) Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells. Circ Res 92:623\u2013629","journal-title":"Circ Res"},{"key":"2534_CR41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s002280050387","volume":"53","author":"A Vermeire","year":"1998","unstructured":"Vermeire A, Remon JP, Rosseel MT, Belpaire F, Devulder J, Bogaert MG (1998) Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients. Eur J Clin Pharmacol 53:325\u2013330","journal-title":"Eur J Clin Pharmacol"},{"key":"2534_CR42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-2999(99)00633-0","volume":"383","author":"JR Walker","year":"1999","unstructured":"Walker JR, King M, Izzo E, Koob GF, Pasternak GW (1999) Antagonism of heroin and morphine self-administration in rats by the morphine-6\u03b2-glucuronide antagonist 3-Omethylnaltrexone. Eur J Pharmacol 383:115\u2013119","journal-title":"Eur J Pharmacol"},{"key":"2534_CR43","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1213\/01.ANE.0000152192.23851.40","volume":"100","author":"Y Wang","year":"2005","unstructured":"Wang Y, Mitchell J, Moriyama K, Kim KJ, Sharma M, Xie GX, Palmer PP (2005) Age-dependent morphine tolerance development in the rat. Anesth Analg 100:1733\u20131739","journal-title":"Anesth Analg"},{"key":"2534_CR44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0378-4347(93)80304-M","volume":"615","author":"D Wielbo","year":"1993","unstructured":"Wielbo D, Bhat R, Chari G, Vidyasagar D, Tebbett IR, Gulati A (1993) High performance liquid chromatographic determination of morphine and its metabolites in plasma using diode-array detection. J Chromatogr 615:164\u2013168","journal-title":"J Chromatogr"}],"updated-by":[{"DOI":"10.1007\/s00213-012-2695-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2012,3,31]],"date-time":"2012-03-31T00:00:00Z","timestamp":1333152000000}}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2534-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2534-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:08:46Z","timestamp":1741835326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,21]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["2534"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2534-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00213-012-2695-z","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,21]]}}}